Bezmialem Vakif University Medical Faculty, Istanbul, Turkey.
Department of Obstetrics and Gynecology, Bezmialem Vakif University Medical Faculty, Istanbul, Turkey.
J Invest Surg. 2021 Aug;34(8):897-901. doi: 10.1080/08941939.2019.1705442. Epub 2020 Jan 6.
The etiology of endometriosis is complex and various theories have been postulated. Endometriosis pathogenesis involves genetic susceptibility, immunologic alterations and inflammatory prerequisite pathways. In this pilot experimental animal study we wanted to investigate the effects of cabergoline and micronized progesterone on a rat endometriosis model.
All rats were provided and housed in the animal laboratory of the Experimental Research Center of Bezmialem Vakif University. This was a placebo controlled randomized trial. The endometriosis model consisted of autotransplantation of endometrial tissue on 21 adult Sprague-Dawley rats. Endometriosis formation by second-look laparotomy was confirmed 8 weeks later. After measuring the endometriosis implant area the rats were randomized into three intervention groups: cabergoline treatment group, micronized progesterone treatment group and the control group. Four weeks after treatment, a third laparotomy was performed to remeasure implant volumes. Endometriotic implants were obtained for histopathological and immunohistochemical analysis.
After 4 weeks of treatment endometriosis implant sizes diminished in all groups. There was no statistically significant difference regarding implant size volume before and after treatment among the groups. The peritoneal histopathology and immunohistochemistry showed no difference with regards to IL-6 and TNF-α staining among groups.
We conclude that oral treatment of cabergoline and micronized progesterone for 4 weeks was not statistically effective in endometriotic implant regression. However, we believe further studies are warranted. Treatment for longer durations or via different routes may be investigated in further studies. When ethically applicable other mammals may be considered such as baboons.
子宫内膜异位症的病因复杂，提出了各种理论。子宫内膜异位症的发病机制涉及遗传易感性、免疫改变和炎症前途径。在这项初步的动物实验研究中，我们旨在研究卡麦角林和米诺孕素对子宫内膜异位症大鼠模型的影响。
所有大鼠均由贝济米耶勒夫大学实验研究中心提供和饲养。这是一项安慰剂对照随机试验。子宫内膜异位症模型由 21 只成年 Sprague-Dawley 大鼠自身子宫内膜组织移植组成。8 周后通过二次剖腹探查确认子宫内膜异位症的形成。测量子宫内膜异位症种植面积后，将大鼠随机分为三组干预组：卡麦角林治疗组、米诺孕素治疗组和对照组。治疗 4 周后，进行第三次剖腹术以重新测量种植体体积。获取子宫内膜异位症种植体进行组织病理学和免疫组织化学分析。
治疗 4 周后，所有组的子宫内膜异位症种植体大小均减小。各组治疗前后种植体体积无统计学差异。腹膜组织病理学和免疫组织化学显示各组 IL-6 和 TNF-α 染色无差异。
我们得出结论，卡麦角林和米诺孕素口服治疗 4 周对子宫内膜异位症种植体消退没有统计学上的显著效果。然而，我们认为还需要进一步的研究。可能需要进一步研究更长时间或通过不同途径的治疗。在伦理上可行的情况下，也可以考虑其他哺乳动物，如狒狒。
